Xi Zhan1, Wei Yan2, Ying Wang3, Qing Li4, Xuhua Shi5, Yanli Gao6, Qiao Ye7. 1. Beijing Institute of Respiratory Medicine, Department of Respiratory Medicine and Critical Care, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China. zhanxi99@hotmail.com. 2. Hunan Prevention and Treatment Institute for Occupational Diseases, Changsha, 410007, Hunan, China. 3. Beijing Institute of Respiratory Medicine, Department of Respiratory Medicine and Critical Care, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China. 4. Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China. 5. Department of Rheumatology and Autoimmune Diseases, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China. 6. Department of Radiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China. 7. Department of Occupational Medicine and Toxicology, Capital Medical University, Beijing, 100020, China.
Abstract
BACKGROUND: Anti-synthetase syndrome (ASSD) is a chronic autoimmune condition characterized by antibodies directed against an aminoacycl transfer RNA synthetase (ARS) along with a group of clinical features including the classical clinical triad: inflammatory myopathy, arthritis, and interstitial lung disease (ILD). ASSD is highly heterogenous due to different organ involvement, and ILD is the main cause of mortality and function loss, which presents as different patterns when diagnosed. We designed this retrospective cohort to describe the clinical features and disease behaviour of ASSD associated ILD. METHODS: Data of 108 cases of ASSD associated ILD were retrospectively collected in Beijing Chaoyang Hospital from December 2017 to March 2019. Data were obtained from the Electronic Medical Record system. Patients were divided into 5 groups according to distinct aminoacyl tRNA synthetase (ARS) antibodies. RESULTS: Overall, 108 consecutive patients were recruited. 33 were JO-1 positive, 30 were PL-7 positive, 23 were EJ positive, 13 were PL-12 positive and 9 were OJ positive. The JO-1 (+) group had a significant higher rate of mechanic's hand (57.6%) than other 4 groups. Polymyositis/dermatomyositis (PM/DM) was diagnosed in 25 (23.1%) patients and no difference was observed among the 5 groups. The PL-7 (+) group had a higher frequency of UIP pattern (13.3%) than the other 4 groups but the difference was not significant, and the EJ (+) group had the most frequent OP pattern (78.2%), which was significantly higher than the PL-7 (+) (P < 0.001) and PL-12 (+) groups (P = 0.025). The median follow-up time was 10.7 months, during which no patients died. All received prednisone treatment, with or without immunosuppressants. At the 6-month follow-up, 96.3% of all patients (104/108) had a positive response to therapy, the JO-1 (+) and EJ (+) groups had a significantly higher improvement of forced vital capacity than the other 3 groups (P < 0.05), and the PL-7 group had the lowest FVC improvement (P < 0.05). The JO-1 (+) group and EJ (+) group had significantly higher anti-Ro-52 positive occurrence than the other 3 groups (P < 0.05). CONCLUSION: Anti PL-7 antibody had the same frequency as anti-JO-1 in ASSD-ILD, in which the ILD pattern was different with distinct anti-ARS antibodies. Most ASSD-ILD had a positive response to steroid therapies, with or without immunosuppressants. The PL-7 (+) group had the highest occurrence of UIP pattern, and a significantly lower response to therapy.
BACKGROUND: Anti-synthetase syndrome (ASSD) is a chronic autoimmune condition characterized by antibodies directed against an aminoacycl transfer RNA synthetase (ARS) along with a group of clinical features including the classical clinical triad: inflammatory myopathy, arthritis, and interstitial lung disease (ILD). ASSD is highly heterogenous due to different organ involvement, and ILD is the main cause of mortality and function loss, which presents as different patterns when diagnosed. We designed this retrospective cohort to describe the clinical features and disease behaviour of ASSD associated ILD. METHODS: Data of 108 cases of ASSD associated ILD were retrospectively collected in Beijing Chaoyang Hospital from December 2017 to March 2019. Data were obtained from the Electronic Medical Record system. Patients were divided into 5 groups according to distinct aminoacyl tRNA synthetase (ARS) antibodies. RESULTS: Overall, 108 consecutive patients were recruited. 33 were JO-1 positive, 30 were PL-7 positive, 23 were EJ positive, 13 were PL-12 positive and 9 were OJ positive. The JO-1 (+) group had a significant higher rate of mechanic's hand (57.6%) than other 4 groups. Polymyositis/dermatomyositis (PM/DM) was diagnosed in 25 (23.1%) patients and no difference was observed among the 5 groups. The PL-7 (+) group had a higher frequency of UIP pattern (13.3%) than the other 4 groups but the difference was not significant, and the EJ (+) group had the most frequent OP pattern (78.2%), which was significantly higher than the PL-7 (+) (P < 0.001) and PL-12 (+) groups (P = 0.025). The median follow-up time was 10.7 months, during which no patientsdied. All received prednisone treatment, with or without immunosuppressants. At the 6-month follow-up, 96.3% of all patients (104/108) had a positive response to therapy, the JO-1 (+) and EJ (+) groups had a significantly higher improvement of forced vital capacity than the other 3 groups (P < 0.05), and the PL-7 group had the lowest FVC improvement (P < 0.05). The JO-1 (+) group and EJ (+) group had significantly higher anti-Ro-52 positive occurrence than the other 3 groups (P < 0.05). CONCLUSION: Anti PL-7 antibody had the same frequency as anti-JO-1 in ASSD-ILD, in which the ILD pattern was different with distinct anti-ARS antibodies. Most ASSD-ILD had a positive response to steroid therapies, with or without immunosuppressants. The PL-7 (+) group had the highest occurrence of UIP pattern, and a significantly lower response to therapy.
Authors: Samuel A Yousem; Frank Schneider; David Bi; Chester V Oddis; Kevin Gibson; Rohit Aggarwal Journal: Hum Pathol Date: 2014-02-06 Impact factor: 3.466
Authors: Ane Labirua-Iturburu; Albert Selva-O'Callaghan; Melinda Vincze; Katalin Dankó; Jiri Vencovsky; Benjamin Fisher; Peter Charles; Maryam Dastmalchi; Ingrid E Lundberg Journal: Medicine (Baltimore) Date: 2012-07 Impact factor: 1.889
Authors: Rohit Aggarwal; Elaine Cassidy; Noreen Fertig; Diane Carol Koontz; Mary Lucas; Dana P Ascherman; Chester V Oddis Journal: Ann Rheum Dis Date: 2013-02-19 Impact factor: 19.103
Authors: I Marie; E Hachulla; P Chérin; S Dominique; P-Y Hatron; M-F Hellot; B Devulder; S Herson; H Levesque; H Courtois Journal: Arthritis Rheum Date: 2002-12-15
Authors: Lorenzo Cavagna; Ernesto Trallero-Araguás; Federica Meloni; Ilaria Cavazzana; Jorge Rojas-Serrano; Eugen Feist; Giovanni Zanframundo; Valentina Morandi; Alain Meyer; Jose Antonio Pereira da Silva; Carlo Jorge Matos Costa; Oyvind Molberg; Helena Andersson; Veronica Codullo; Marta Mosca; Simone Barsotti; Rossella Neri; Carlo Scirè; Marcello Govoni; Federica Furini; Francisco Javier Lopez-Longo; Julia Martinez-Barrio; Udo Schneider; Hanns-Martin Lorenz; Andrea Doria; Anna Ghirardello; Norberto Ortego-Centeno; Marco Confalonieri; Paola Tomietto; Nicolò Pipitone; Ana Belen Rodriguez Cambron; María Ángeles Blázquez Cañamero; Reinhard Edmund Voll; Sarah Wendel; Salvatore Scarpato; Francois Maurier; Massimiliano Limonta; Paolo Colombelli; Margherita Giannini; Bernard Geny; Eugenio Arrigoni; Elena Bravi; Paola Migliorini; Alessandro Mathieu; Matteo Piga; Ulrich Drott; Christiane Delbrueck; Jutta Bauhammer; Giovanni Cagnotto; Carlo Vancheri; Gianluca Sambataro; Ellen De Langhe; Pier Paolo Sainaghi; Cristina Monti; Francesca Gigli Berzolari; Mariaeva Romano; Francesco Bonella; Christof Specker; Andreas Schwarting; Ignacio Villa Blanco; Carlo Selmi; Angela Ceribelli; Laura Nuno; Antonio Mera-Varela; Nair Perez Gomez; Enrico Fusaro; Simone Parisi; Luigi Sinigaglia; Nicoletta Del Papa; Maurizio Benucci; Marco Amedeo Cimmino; Valeria Riccieri; Fabrizio Conti; Gian Domenico Sebastiani; Annamaria Iuliano; Giacomo Emmi; Daniele Cammelli; Marco Sebastiani; Andreina Manfredi; Javier Bachiller-Corral; Walter Alberto Sifuentes Giraldo; Giuseppe Paolazzi; Lesley Ann Saketkoo; Roberto Giorgi; Fausto Salaffi; Jose Cifrian; Roberto Caporali; Francesco Locatelli; Enrico Marchioni; Alberto Pesci; Giulia Dei; Maria Rosa Pozzi; Lomater Claudia; Jorg Distler; Johannes Knitza; George Schett; Florenzo Iannone; Marco Fornaro; Franco Franceschini; Luca Quartuccio; Roberto Gerli; Elena Bartoloni; Silvia Bellando Randone; Giuseppe Zampogna; Montserrat I Gonzalez Perez; Mayra Mejia; Esther Vicente; Konstantinos Triantafyllias; Raquel Lopez-Mejias; Marco Matucci-Cerinic; Albert Selva-O'Callaghan; Santos Castañeda; Carlomaurizio Montecucco; Miguel Angel Gonzalez-Gay Journal: J Clin Med Date: 2019-11-18 Impact factor: 4.241
Authors: Angeles S Galindo-Feria; Antonella Notarnicola; Ingrid E Lundberg; Begum Horuluoglu Journal: Front Immunol Date: 2022-05-13 Impact factor: 8.786
Authors: Matthew Wells; Sughra Alawi; Kyaing Yi Mon Thin; Harsha Gunawardena; Adrian R Brown; Anthony Edey; John D Pauling; Shaney L Barratt; Huzaifa I Adamali Journal: Front Med (Lausanne) Date: 2022-09-14